advanced search

Injectable Drug Delivery97

Issue No #97 May 2019  May 10th, 2019


Download PDF


Inside the magazine

SIMULATING STRESSFUL, EMERGENCY-USE SCENARIOS DURING USABILITY TESTS OF INJECTION DEVICES
EXPERT VIEW
Allison Strochlic
SIMULATING STRESSFUL, EMERGENCY-USE SCENARIOS DURING USABILITY TESTS OF INJECTION DEVICES
Allison Strochlic highlights the importance of simulating environments that are as realistic as possible when conducting usability tests of emergency-use injection devices, and provides case studies with examples of how to create more realistic tests.
A PATIENT CENTRIC AND PHARMA COMPANY CENTRIC PREFILLED WEARABLE BOLUS INJECTOR
WEARABLES
Jesper Roested
Subcuject
A PATIENT CENTRIC AND PHARMA COMPANY CENTRIC PREFILLED WEARABLE BOLUS INJECTOR
Jesper Roested explains why the pharma/biotech drug development process often means device selection occurs after Phase II despite the advantages of earlier selection being well understood, and how this then precludes the selection of novel primary packaging and delivery systems.
COMPANY SHOWCASE: Cristal Therapeutics
INJECTION
Dr Cristianne Rijcken
Cristal Therapeutics
COMPANY SHOWCASE: Cristal Therapeutics
Over the past year, Cristal Therapeutics has transitioned from a research-stage start-up to a fully fledged, clinical-stage business with a promising pipeline of proprietary drug candidates. This diverse pipeline together with the proprietary nanoparticle platform, CriPec®, presents a broad range of promising late- and early-stage partnering opportunities for companies active in the oncology space.
10TH GLOBAL DRUG DELIVERY & FORMULATION (DDF) SUMMIT, Berlin, Germany, March 11–13, 2019
CONFERENCE REVIEW
Josh Lowth
10TH GLOBAL DRUG DELIVERY & FORMULATION (DDF) SUMMIT, Berlin, Germany, March 11–13, 2019
The second week of March is a key date in the delivery and formulation event calendar. This is when the good and the great of Europe’s pharmaceutical development community gather in Berlin, Germany, for the DDF Summit – a high-level scientific event for industry and academia.
A NEW MULTI-COMPENDIA MODIFIED BETA-CYCLODEXTRIN, KLEPTOSE<sup>®</sup> HPB-LB PARENTERAL GRADE
INJECTION
Dr Elham Blouet
Roquette
A NEW MULTI-COMPENDIA MODIFIED BETA-CYCLODEXTRIN, KLEPTOSE® HPB-LB PARENTERAL GRADE
Elham Blouet introduces the latest addition to the company’s range of beta-cyclodextrins, and outlines the benefits it brings.
TECHNOLOGY SHOWCASE: Credence MedSystems Multi-Site™ Injection System
INJECTION
John Merhige
Credence MedSystems
TECHNOLOGY SHOWCASE: Credence MedSystems Multi-Site™ Injection System
Credence MedSystems introduces the Multi-Site™ Injection System – a product that addresses specific needs in the high-growth dermal filler market.
SELECTING THE RIGHT PRIMARY CONTAINER FOR INJECTABLES IN ACUTE CARE
INJECTION
Alfred Harvey
BD (Becton Dickinson & Company)
SELECTING THE RIGHT PRIMARY CONTAINER FOR INJECTABLES IN ACUTE CARE
Alfred Harvey explains why it’s important to select the right primary container presentation – and what can happen if you get it wrong.
ALTERING PATIENT TREATMENT: HOW SC DELIVERY CAN HELP PATIENTS MANAGE CHRONIC CONDITIONS
WEARABLES
Victoria Morgan
West Pharmaceutical Services
ALTERING PATIENT TREATMENT: HOW SC DELIVERY CAN HELP PATIENTS MANAGE CHRONIC CONDITIONS
Victoria Morgan looks at the benefits of combining an active pharmaceutical product with a novel subcutaneous delivery device, and highlights some of the partnerships West has with biopharmaceutical and other companies, which have led to market launches of products incorporating its on-body delivery system.
MICROLITRE DOSING WITH PREFILLABLE SYRINGES – WHEN DOES A DEVICE MAKE SENSE?
EXPERT VIEW
Dr Gautam N Shetty
MICROLITRE DOSING WITH PREFILLABLE SYRINGES – WHEN DOES A DEVICE MAKE SENSE?
Gautam Shetty and Bernd Zeiss outline factors that need to be weighed when considering a device-based approach to microlitre injections.
TRAINING DEVICES INCREASE PATIENT ENGAGEMENT AND ADHERENCE – CREATING BETTER OUTCOMES
INJECTION
Erin Miller
Noble
TRAINING DEVICES INCREASE PATIENT ENGAGEMENT AND ADHERENCE – CREATING BETTER OUTCOMES
Erin Miller outlines a study looking at how patients interact with training resources during the first 14 days of a new treatment – and how training devices can help increase confidence, adherence and, ultimately, overall outcomes for the millions of patients who manage their diseases through self-injection.
MULTILAYER PLASTIC VIALS & SYRINGES FOR BIOLOGICS
INJECTION
Takuya Minezaki
Mitsubishi Gas Chemical
MULTILAYER PLASTIC VIALS & SYRINGES FOR BIOLOGICS
Dr Takuya Minezaki and Tomohiro Suzuki, provide an overview of the company’s OXYCAPT™ Vials and Syringes, explaining how their multi-layered polymer material delivers the advantages of both COP and glass, and is especially suitable for biotherapeutics.
PRODUCT SHOWCASE: Zwickroell Autoinjector Testing Platform
INJECTION
Wolfgang Moersch
ZwickRoell
PRODUCT SHOWCASE: Zwickroell Autoinjector Testing Platform
ZwickRoell introduces RoboTest, its automated autoinjector testing platform, which works together with the AutoEdition 3 automation software ad testXpert III testing software.
PATIENT TOLERABILITY WITH HIGH-VISCOSITY, LARGE-VOLUME SUBCUTANEOUS INFUSIONS
EXPERT VIEW
Jennifer Estep
PATIENT TOLERABILITY WITH HIGH-VISCOSITY, LARGE-VOLUME SUBCUTANEOUS INFUSIONS
Jennifer King and Matthew J Huddleston discuss the advantages of subcutaneous drug delivery and how these have yet to be fully harnessed in currently marketed therapeutics.
SKIN-MOUNTABLE FLEXIBLE NEEDLE PATCH FOR MINIMALLY INVASIVE CONTROLLED DRUG DELIVERY
EARLY INSIGHT
Dr Chi Hwan Lee
Weldon School of Biomedical Engineering
SKIN-MOUNTABLE FLEXIBLE NEEDLE PATCH FOR MINIMALLY INVASIVE CONTROLLED DRUG DELIVERY
Chi Hwan Lee and Eun Kwang Lee introduce a skin-mountable flexible needle patch and discuss its applications in non-invasive drug delivery applications.
NEXT-LEVEL FUTURE MANUFACTURING FOR MEDICAL TECHNOLOGY
INJECTION
Berthold Schopferer
Zahoransky
NEXT-LEVEL FUTURE MANUFACTURING FOR MEDICAL TECHNOLOGY
Berthold Schopferer explains the lengths the production equipment company goes to in its efforts to ensure the customer is always king.
ENABLING SUBCUTANEOUS DELIVERY OF BIOLOGICS
INJECTION
Elektrofi
ENABLING SUBCUTANEOUS DELIVERY OF BIOLOGICS
Elektrofi introduces Elektroject™, a gentle process for the production of ultra-high concentration protein formulations, that maintains a syringeable format and excellent protein stability, making the switch from intravenous to subcutaneous delivery viable for numerous biotherapeutics, including monoclonal antibodies.
A RE-USABLE CONNECTED AUTOINJECTOR CUSTOMISED FOR THE COMPANION<sup>®</sup> SAFETY SYRINGE SYSTEM
INJECTION
Bjarne Sørensen
Phillips-Medisize
A RE-USABLE CONNECTED AUTOINJECTOR CUSTOMISED FOR THE COMPANION® SAFETY SYRINGE SYSTEM
Bjarne Sørensen and John A. Merhige explore the latest developments in modular autoinjector platforms and the benefits for end users and pharmaceutical customers. They also discuss the two companies’ recent partnership for the development of a combined system that capitalises on important synergies between two compatible technologies.
Top